Out of the 8,200 abstracts accepted for the ASH 2025 annual congress, we highlight several key abstracts that discuss targeted treatment strategies for lymphoid and myeloid malignancies, especially the high-impact ones showcased in the late-breaking abstract and plenary sessions.

The open-label, randomized phase III trial DREAMM-7 compared the safety and efficacy of two combination treatments, BVd (Belantamab-Mafodotin, Bortezomib, dexamethasone) and DVd (Daratumumab + Vd) in patients with refractory and relapsing Multiple Myeloma (R/R MM) who have received ≥ 1 line of treatment (LOT).

Targeted agents such as Bruton tyrosine kinase inhibitor (BTKi; e.g., ibrutinib) and B-cell lymphoma-2 inhibitors (BCL2i) have emerged for the treatment of Chronic Lymphocytic Leukemia (CLL).

Standard initial treatment for acute myeloid leukemia (AML) patients varies based on age and fitness. Typically, younger and fit patients, under 65 years old, receive intensive induction chemotherapy (IC), commonly known as the “7+3” regimen, which consists of cytarabine and an anthracycline, followed by consolidation therapy, allogeneic stem-cell transplantation (HCT), or a combination of both.